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Stroke is the major cause of death and the leading cause of dis-
ability worldwide,
1 and the best treatment is prevention by con-
trolling the risk factors for atherosclerosis, such as hyperten-
sion, diabetes, and hyperlipidemia.
2 Atherosclerosis is charac-
terized by progressive accumulation of lipids and inflamma-
tory cells within the artery wall.
3,4 It is a diffuse systemic disea-
se;3 however, some atherosclerotic plaques are prone to rup-
ture and thereby cause sudden thromboembolic vascular 
occlusion, while others are clinically silent.
5-7 Therefore, to 
prevent stroke, clinicians need to localize high-risk vulnerable 
plaques, which has been a great challenge to date.
If prevention fails and ischemic stroke occurs, some patients 
can be treated with thrombolytic drugs that dissolve blood 
clots obstructing blood flow to the brain.
8-10 The likelihood of 
recovery with little or no disability is at least 30% higher in 
treated patients than in those who do not receive the drugs in 
time.
11 However, thrombolytic treatment in itself can cause the 
complication of intracranial hemorrhage, and it is this compli-
cation that hampers the wider application of thrombolytic 
therapy.
12-14 Identifying predictors for the occurrence of throm-
bolysis-induced symptomatic intracranial hemorrhage is a 
very important objective that would make these therapies 
safer.
15,16 In a similar context, predicting thrombolytic resis-
tance in an individual patient would allow more effective stra-
tification of treatments.
If thrombolysis fails or hemorrhagic complication occurs, 
decompressive surgery-including hemicraniectomy and durot-
omy with temporal lobe resection-remains the most attractive 
option for treating ischemic brain swelling.
17-19 Additional sur-
gery, “strokectomy” of parts of the frontal or temporal lobe, 
may be needed in younger patients who fail to improve.
20 Cur-
rently, surgeons do not have sophisticated intra-operative 
guiding systems to monitor and help control cerebral perfusion, 
allowing them to distinguish and delineate “riskier but salvage-
able” cerebral areas from irrevocably infarcted sites during th-
ese procedures.
Unfortunately, studies based on conventional structural im-
aging tools such as magnetic resonance imaging (MRI) and 
computed tomography (CT) have had limited success in solv-
ing the above-described problems. Molecular imaging can vi-
sualize pathophysiologic alterations and promises to augment 
and supplement anatomy-based imaging.
21-23 This brief review 
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focuses on optical molecular imaging and its potential roles in 
the future of stroke management.
Types of Molecular Imaging
Molecular imaging is defined as the in vivo measurement of 
biological processes at the cellular and molecular levels.
24-26 
Molecular-imaging-based visualization of in vivo pathophysi-
ologic processes could provide information regarding specif-
ic molecular alterations underlying the disease status of indi-
vidual patients in real time.
27-29 By providing molecular in-
formation unobtainable using conventional anatomy-based 
imaging modalities, molecular imaging would allow 1) earlier 
detection of diseases, 2) precise discrimination of the stable 
versus unstable disease status, and 3) both diagnostic and ther-
apeutic quantitative monitoring of disease progression.
30-32 The 
various modalities of molecular imaging (CT/MRI/fluorescent 
optical imaging/positron-emission tomography, PET/single-
photon-emission CT/SPECT/ultrasound) have their own spe-
cific advantages and disadvantages that are related to how the 
images are generated.
21,32
The application of fluorescent proteins or fluorochromes to 
the life sciences during the last 2 decades has considerably ad-
vanced basic and translational biological research, and these 
advances are now beginning to affect clinical practice.
29,33,34 
Fluorescence involves the absorption of light at characteristic 
wavelengths, and the emission of the stored energy at longer 
wavelengths.
35 The advantages of fluorescence as a molecular 
imaging modality include picomolar molecular sensitivity, ab-
sence of ionizing radiation, the possibility of using it in many 
modalities with different scales, and relatively low cost. How-
ever, poor tissue penetration capability is a major obstacle to 
overcome.
36,37 The attenuation of light by tissue is lowest in 
the near-infrared (NIR, 700-900 nm) region, and imaging in 
this region offers 1) markedly less photon absorption by blood 
hemoglobin, lipid, and water, allowing light to penetrate cen-
timeters into the body; and 2) substantially reduced tissue au-
tofluorescence, enabling higher sensitivity detection of tar-
geted NIR fluorescent (NIRF) molecular imaging agents aga-
inst a low background.
31,36,38 This technology can potentially 
be combined with a non-invasive optical tomography system, 
intra-operative NIRF imaging system, or fluorescence-sensing 
catheter-based system.
39 Jaffer et al. recently demonstrated that 
a NIRF-sensing catheter based on a clinical coronary artery 
guidewire could detect in vivo cathepsin B (CatB) protease ac-
tivity in rabbit vessels the size of human coronary arteries in 
real time. 
NIRF imaging requires a much smaller dose of fluorescence 
probes to detect molecules of interest-nanomoles of fluoro-
chromes can be detected, compared to micromoles for MRI or 
millimoles for CT.
31,32 The relatively high spatial resolution 
(typically less than 1 mm) of the catheter-based imaging sys-
tem is another advantage of fluorescence imaging.
39 Scatter 
reduces the spatial resolution of non-invasive fluorescence 
molecular tomography (FMT) relative to using an endoscopic 
imaging device (-1 mm), and is within the range of resolution 
provided by SPECT and PET.
36
Imaging Vulnerability 
of Atherosclerotic Plaques
Studies have demonstrated that the formation of a thrombus 
due to rupture of unstable atherosclerotic plaques, followed by 
thrombotic or embolic occlusion of an artery, is the leading ca-
use of stroke, accounting for up to 80% of cases of ischemic 
stroke in some autopsy series.
10,40 There is a pressing need for 
tools to identify these vulnerable plaques, and thereby identi-
fy patients and lesions at high risk for vascular events, so 
that risk-altering treatments might be offered to improve clini-
cal outcomes. According to the current practice guidelines and 
consensus, a carotid lesion is likely to cause ischemic stroke 
when stenosis of over 60 or 70% is detected by angiography.
41 
However, it has become clear that many strokes are attribut-
able to plaques in the arteries with stenosis of 50% or less, hi-
ghlighting the importance of plaque ruptures as a causative 
mechanism.
42-44 Rupture-prone vulnerable plaques are not 
well identified by conventional measures of stenosis.
45-47 Ul-
trasonic characterization of plaques as heterogeneous or of 
low echodensity on carotid duplex ultrasonography has been 
regarded by some as suitable for detecting unstable plaques, 
but firm conclusions await further studies.
48,49 Plaque size and 
morphology (Fig. 1) are poor substitutes for the molecular 
events that shaped them, and the measurement of underlying 
molecular states provides the best hope for determining the 
propensity to cause complications.
For asymptomatic patients with significant carotid stenosis, 
the number needed to treat to prevent one stroke from any ca-
use at two years is 67, which could increase to 111 to prevent 
one large-artery stroke at 2 years, since not all strokes originate 
from a narrowed internal carotid artery.
50 For symptomatic pa-
tients, endarterectomy is beneficial in the long term even in 
the presence of a contralateral occlusion and increased periop-
erative risk.
51,52 However, from a patient’s standpoint, opting 
for a procedure with a 3-6% immediate perioperative risk to 
reduce a future stroke chance by 6-15% at 5 years in both as-
ymptomatic and symptomatic cases can be daunting.
53 This il-
lustrates the difficulty of weighing the risks and benefits in tr-
eating an individual patient.
51
Characteristic features of vulnerable atherosclerotic plaques 
are accumulation of inflammatory cells inside the plaque (Fig. Molecular Optical Imaging in Stroke
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2), formation of a large lipid core, and thinning of the overly-
ing fibrous cap.
5 Heavily clustered macrophages in and around 
the shoulder region of the cap would secrete matrix-disorga-
nizing proteolytic enzymes such as cathepsins and matrix me-
talloproteinases (MMPs), which could render atherosclerotic 
plaques prone to rupture.
6,54 Thus, inflammatory protease ac-
tivity could be regarded as a hallmark of the plaque vulnera-
bility. In fact, using the Affymetrix gene chip to profile genes 
expressed in stable and unstable atherosclerotic plaques re-
vealed that the expressions of CatB, cathepsin S, and MMP-9 
were up-regulated in unstable atherosclerotic plaques.
55 Taken 
together, these data suggest that imaging protease activity in 
vivo could allow identification of vulnerable plaques.
The Weissleder group and others have developed protease-
sensing NIRF molecular imaging agents.
56-60 Unlike “always-
on” probes such as nonspecific NIRF probes [e.g., indocya-
nine green (ICG)] or targeted NIRF probes relying on affinity 
ligands, the protease-sensing NIRF probes are “optically silent 
at injection” because of intra-molecular autoquenching be-
tween closely spaced fluorochromes. Enzyme-specific prote-
ase-mediated cleavage spatially separates fluorochromes so 
that they become dequenched and brightly fluorescent. Mul-
tiple NIR fluorochromes positioned on a polylysine backbone 
can be activated by CatB.
34 The gelatinase substrate sequence 
GGPRQITAG has been used to synthesize a NIRF probe that 
can be activated by MMP-2/9.
58 Animal studies using these ac-
tivatable probes have shown that in vivo and ex vivo NIRF im-
aging could visualize the protease activity in the aortic or carot-
id atheromata of ApoE knock-out mice (Figs. 3 and 4).
58,59,61,62 
Immunohistochemical analyses demonstrated that the NIRF 
signal precisely reflected the spatial distribution of the in-
flammatory protease activities. In addition, the protease im-
munoreactivity co-localized with Mac-3 or CD-68 positive ma-
crophages. 
Despite the high expectations for and rapidly increasing in-
terest in molecular imaging techniques, there are significant 
challenges in translating the advances from the laboratory to 
the atherosclerosis clinic. As a step toward clinical translation, 
we recently demonstrated that CatB NIRF imaging could re-
liably reflect the anti-atherosclerotic effect of atorvastatin and 
glucosamine as well as the pro-atherosclerotic effect of a high 
cholesterol diet (Fig. 4). We also revealed that plaque popula-
tions were heterogeneous within individuals, with some pla-
ques showing high and others lower CatB-related signals.
61 
Notably, these differences in signal intensity could not be pre-
dicted by visual inspection of the plaques. In every case where 
imaging predicted an inflammatory component in the plaque, 
histological studies confirmed it to be the case.
61 Regarding 
translation steps from animals to humans, catheter-based flu-
orescence imaging systems are likely to be available in the ath-
erosclerosis clinic. In addition, it should be remembered that 
since NIR photons can potentially penetrate >5 centimeters 
into the body, noninvasive FMT systems may eventually detect 
A   B  
Fig. 1. Duplex ultrasonography and an-
giography imaging provide structural in-
formation about carotid atherosclerosis. 
In the carotid sonograph (A), the athero-
sclerotic plaque is shown to have hetero-
geneous echodensity (blue arrows). The 
digital subtraction angiogram (B) shows 
significant atherosclerotic narrowing of 
the internal carotid artery. Current stroke 
practice relies heavily on the degree of 
carotid stenosis, as demonstrated by th-
ese anatomy-based structural imaging 
modalities. Adapted from Kim and Je-
ong
87 with permission from the Korean 
Medical Association. 
Fig. 2. Three-dimensional carotid positron-emission tomography 
and computed tomography angiography imaging. 
18Fluoro-deoxyglu-
cose uptake is elevated in the right carotid artery (blue arrow), refle-
cting increased metabolism due to heavy infiltration of inflammatory 
cells such as macrophages in the atherosclerotic plaque. Adapted 
from Kim and Jeong
87 with permission from the Korean Medical As-
sociation. The numbers on the pseudo-color bar indicate standard 
uptake values.Lee DK et al.
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NIRF signals from human carotid atheromata.
36,37 Moreover, 
the protease-sensing probe is expected to enter clinical trials 
in 2010.
31 Other molecular imaging biomarkers that reflect 
plaque vulnerability include annexin for apoptosis,
63,64 integ-
rins for angiogenesis,
65 and inflammatory cells such as mac-
rophages.
66-68
To summarize, molecular optical imaging could contribute 
to stroke prevention by detecting protease activity in atherosc-
lerotic plaques in vivo; it would thereby serve as a powerful tool 
for evaluating vascular inflammation, for determining individ-
ualized therapeutic strategies including pre-operative plan-
ning, and for monitoring the effects of therapeutic interventions.
Imaging Thrombolytic Resistance
Fibrinolytic therapy, which is the only FDA-approved treat-
ment for acute cerebral infarction, inevitably imposes a hem-
orrhagic risk.
10,13,14 Delayed or intra-arterial thrombolysis is 
associated with higher complication rates, and enormous ef-
fort has been expended to empirically define the risks and 
benefits of thrombolysis at different times after vascular occlu-
sion.
14 Predicting the thrombolytic resistance and hemorrhag-
ic risk in individual patients would be extremely helpful when 
deciding whether or not to perform thrombolytic therapy in in-
dividual patients.
A  
B   C  
Fig. 3. Protease-activatable near-infrared fluorescent (NIRF) imaging to allow the visualization of vulnerable plaques in the aorta of a mouse. 
In the areas positive for cathepsin K (CatK) immunohistochemical staining (A, ×20, red-colored regions), the fluorescence activation of the 
intravenously-injected imaging agent
59 by the CatK cleavage activity is evident in NIRF microscopy imaging of cryosections of the aortic ath-
eromata in an ApoEknock-out mouse fed on a Western diet (B, ×20); the co-localization is illustrated by the yellow arrowheads. Higher magni-
fication (C, ×40) reveals the derangement of undulated elastic fibers (red arrow), suggesting matrix disorganization. A stable portion of the ar-
tery without CatK activity or elastin degradation is indicated by the blue arrow. Taken together, these results suggest that molecular optical 
imaging can reflect matrix-disorganizing protease activity, allowing identification of rupture-prone inflammatory plaques.
Fig. 4. Light imaging and protease-sensing molecular optical imaging to reflect the pro-atherosclerotic and anti-atherosclerotic effects of a high 
cholesterol diet and atorvastatin treatment, respectively. Eight-week-old ApoE knock-out mice were put on various diets: 1) a normal chow diet 
(left two panels), 2) a Western diet (center two panels), and 3) a Western diet with atorvastatin for 14 weeks (right two panels). The cathepsin 
B (CatB) NIRF imaging shows that the CatB-related signal is stronger in the mouse on a high cholesterol diet than in the mouse on a normal 
diet. In the animal on a Western diet with atorvastatin, the CatB-related signal is as low as that in the animal on a normal diet. Note that 
plaques that appear similar in the color photograph (of the animal on a Western diet) have different signal intensities in the CatB image (arrows 
and arrowheads). Adapted from Kim et al.
88 with permission from the Korean Neurological Association. NIRF: near-infrared fluorescent. 
Normal diet Western diet Western diet
+
Atorvastatin
Light Light Light NIRF NIRF NIRFMolecular Optical Imaging in Stroke
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As a first step toward imaging thrombolytic resistance in 
vivo, we and others chose to devise and characterize a molec-
ular imaging agent to probe for the activity of factor XIII (FX-
III) enzyme, a thrombin activated transglutaminase.
69-71 The 
FXIII probe contains NIR fluorochromes attached to the pep-
tide sequence NQEQVSPLTLLK, which is specifically recog-
nized by the coagulation enzyme as its substrate. The normal 
function of activated FXIII (FXIIIa) enzyme is to stabilize a 
thrombus by cross-linking fibrin fibers-thus increasing the 
tensile strength-so as to covalently bind molecules that impede 
plasmin activity, such as α2-antiplasmin.
72
Imaging this coagulation enzyme activity may be useful to 
staging the thrombotic disease when determining the appro-
priate therapy by clarifying the acute-versus-chronic state of 
the clot, which is difficult or impossible to achieve with ana-
tomic imaging only. When the probe was injected intravenous-
ly into mice with ferric-chloride-induced thrombi in the femo-
ral artery, the FXIIIa-related NIRF signal intensity was pro-
portional to the age of the thrombi.
71
The activity of FXIIIa enzyme is expected to change far 
more rapidly than the clot volume, and may serve as an early 
predictor of the success or failure of a therapeutic regimen.
73 
In this context, we investigated whether FXIIIa imaging could 
reflect treatment effects. To study the effect of heparin in a mo-
use model of cerebral venous thrombosis, heparin was admi-
nistered immediately before thrombus induction and the FX-
III probe was injected 3 hours later.
70 The FXIIIa-related NIRF 
signal, captured through a cranial window using an intravital 
fluorescence microscope (Fig. 5), was significantly weaker in 
the heparin-pretreated group than in the untreated group. Nota-
bly, the therapeutic response to the anticoagulation treatment 
could be monitored in real time. We are currently studying if 
FXIIIa imaging can predict thrombolytic resistance in an ar-
terial stroke model. Thrombolytic resistance is likely multifac-
torial in origin, and hence other imaging or plasma biomarkers 
of thrombolytic resistance merit further investigations, such 
as plasminogen activator inhibitor-1, α2-antiplasmin, and fac-
tor V.
74,75
The future combination of molecular optical imaging with 
fluorescence-sensing intra-arterial catheter systems is expect-
ed to be suitable for clinical application, with molecular diag-
nosis guiding therapy with fibrinolytic agents or thrombin in-
hibitors and their successor drugs in acute ischemic stroke. 
This approach may allow discrimination of thrombi that would 
be resistant to chemical thrombolytic agents. Early triage to 
mechanical recanalization and clot retrieval methods would be 
rational when chemical thrombolysis is expected to fail, if pa-
tients could be triaged appropriately to these treatments (Fig. 6).
Real-Time Intra-Operative Imaging 
of Cerebral Perfusion and Penumbra
Intra-operative molecular imaging may assist neurosurgeons 
who are performing procedures such as post-stroke decom-
pression surgery or revascularization operations to visualize 
cerebral perfusion and penumbra in real time. Woitzik and 
colleagues
76 introduced intraoperative cerebral videoangiogra-
phy, an imaging system integrated into the surgical microscope, 
Fig. 5. In vivo factor-XIII (FXIII) imaging 
to localize venous cerebral thrombi in a 
mouse. A mouse with cerebral venous 
th rombosis and a cranial window (inset) 
received a fluorescent imaging agent 
(A15) that could visualize the activity of 
the FXIII coagulation enzyme. Intravital 
microscopy imaging showed that the im-
aging agent initially remained intravas-
cular, producing a cerebral angiogram 
(A). The NIRF signal subsequently de-
creased in all but thrombosed areas (B; 
image captured at 30 minutes after A15 
injection). The representative H&E sec-
tions (C and D; acquired by cutting along 
the yellow and blue lines of B, respec-
tively) of the superficial brain at the loca-
tion of the frontal tip of the thrombus sig-
nal (black arrow in B) show the corres-
ponding thrombus (yellow and blue 
arrows, respectively). In addition to the 
main body of the thrombus, a smaller 
thrombus in the adjacent vessel (asterisk 
in D) exhibits an FXIII-related NIRF sig-
nal (asterisk in B). Modified from Kim et 
al.
70 with permission from the Korean 
Neurological Association. Scale bars: A, 
1 mm; B, 150 μm. NIRF: near-infrared flu-
orescent.
A  
C   D  
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which allowed 1) real-time imaging of the cortical blood flow 
in patients undergoing decompressive craniectomy and 2) cor-
tical perfusion areas to be stratified into ischemic core and pen-
umbral areas. They used ICG, which binds tightly to plasma pro-
teins and becomes confined to the vascular system; its short 
half-life and emission at a NIR wavelength (835 nm) make it 
an advantageous contrast agent for in vivo angiography. A ce-
rebral blood flow index (the ratio of the difference in fluores-
cence intensity and rise time) was calculated to determine flow 
maps that were used to assign a significant portion of tissue 
(15-37%) to the penumbra,
76 which is a potential target to ma-
ximize benefits from the decompressive craniectomy, which in 
turn reduces intracranial pressure and improves cerebral blood 
flow.
77
Clinically, in vivo retinal angiography with ICG has long 
been used to visualize neovascularization and hemorrhage in 
retinal and choroidal tissues.
78 In a mouse model with a crani-
al window, we showed that cerebral ICG-based angiography 
could reveal permeability of the blood-brain barrier by sens-
ing ICG leakage from cerebral vessels due to thrombosis-in-
duced venous hypertension in real time in vivo.
70 The technique 
was recently used to evaluate cortical microvascularization to 
compensate for a reduced cerebral blood flow in Moyamoya 
disease.
79 ICG-based angiography demonstrated that the mi-
crovascular density and diameter were significantly elevated 
in patients with Moyamoya disease.
In addition to the cerebral perfusion status, the penumbral 
area could be defined by various physiological parameters in-
cluding decreased pH due to increased intracellular lactate 
accumulation.
80-82 pH-Activatable molecular optical imaging 
probes conjugated to a cancer-targeting monoclonal antibody 
were developed recently.
83 The probes consist of a boron-dipy-
rromethene (BODIPY) as a fluorophore and a dialkylated 
aniline that renders the fluorophore fluorescent at different aci-
dic pHs. BODIPY dye with a nonprotonated form of dialkylat-
ed aniline is nonfluorescent, whilst the dye with a protonated 
form of aniline is highly fluorescent. Conjugation of the probe 
to a cancer-specific monoclonal antibody, trastuzumab, leads to 
recognition and internalization by HER2-positive cancer cells 
via the endosomal-lysosomal degradation pathway. An acidic 
pH in the lysosome then turns on the fluorophore, and hence 
the probe offers tumor specificity with a minimal background 
signal. It should be noted that the imaging agent is not an “al-
ways-on” probe like conventional targeted probes. Instead, it 
becomes fluorescent under specific conditions, which impro-
ves the specificity and sensitivity as in the case of protease ac-
Fig. 6. Potential role of molecular optical imaging to guide thrombolytic therapy in acute stroke patients. Currently there is no established 
clinical tool for characterizing the resistance of a thrombus to thrombolytic drugs. One of the key determinants of thrombolytic resistance is 
fibrin cross-linking resulting from the activity of FXIII. FXIII activity or the density of cross-linked fibrin mesh cannot be measured in vivo (A). 
One patient (who was later found to have had a highly cross-linked clot) had received a urokinase infusion in the setting of acute stroke. It 
took a long time to lyse the thrombus occluding (red circle in B) the left middle cerebral artery (MCA). This resistant thrombus was associat-
ed with not only delayed recanalization but also with high doses of thrombolytic drug delivered into MCA perforating arteries or collateral ar-
teries (blue arrows in B and C). The patient exhibited post-thrombolysis hemorrhage in the basal ganglia and corona radiata (red arrow in 
D). In the near future, the thrombolytic resistance of a thrombus is likely to become measurable in vivo and in real time using a fluores-
cence-sensing fiber-optic catheter and molecular imaging probes to characterize the nature of the thrombus (E). This could be of great ben-
efit in triaging patients to appropriate treatments (F and G).
A  B 
F  E  D  G 
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tivatable probes. More importantly, since the proton pump is 
required to maintain the acidic condition in the lysosome, only 
viable cancer cells can be visualized by the probe. This kind of 
pH-sensing probe may be useful in delineating cerebral pen-
umbra and infarcted tissues.
Future Directions  
of Molecular Imaging Research
Molecular imaging researchers are actively pursuing 1) the 
development of novel molecular imaging strategies, particu-
larly multi-modal molecular imaging, 2) innovations in molecu-
lar imaging-based theranostics, and 3) bench-to-bedside tran-
slation of associated cutting-edge technologies. Cardiovascu-
lar and neurovascular molecular optical imaging researchers 
pursue similar aims. Multi-modal molecular imaging probes 
are detectable by optical, MRI, and nuclear approaches simul-
taneously, which provides both high molecular sensitivity and 
high anatomical resolution as shown by Kircher et al.
84 com-
bined MR and optical imaging. Nahrendorf et al. labeled de-
xtranated and DTPA-modified magnetofluorescent nanopar-
ticles with 
64Cu to yield a macrophage-targeted trimodality 
reporter for combined MRI, PET, and optical imaging.
67
Combining diagnostic molecular imaging with therapeutic 
(theranostic) approaches would allow diseases to be detected 
at an early stage, drug delivery to desired targets to be monito-
red, quantification of the therapeutic efficacy in an individual 
patient in vivo, and the treatment for the patient to be tailored 
based on the imaging results. The development and utilization 
of protease-mediated photodynamic agents could be regard-
ed as a theranostic approach.
85 The agents are nontoxic in their 
native state, but they become fluorescent and produce singlet 
oxygen on protease conversion; after being delivered and ac-
tivated in and around the macrophages infiltrating vulnerable 
plaques, intravenously injected theranostic agents are expect-
ed to not only visualize rupture-prone plaques but also stabilize 
them as a photodynamic therapy while avoiding systemic pho-
totoxicity.
Conclusion
Healthcare in the 21
st century is evolving to be personalized, 
predictive, and preventive. Molecular imaging provides a funda-
mentally new type of information that allows a timely and pre-
cise assessment of pathophysiologic states at the cellular and 
molecular levels, thereby complementing that available from 
anatomically based imaging modalities. Molecular optical im-
aging will provide the information needed to provide personal-
ized stroke care. Most importantly, well-designed translational 
animal studies and human trials will be key to establishing the 
use of molecular imaging tools in clinical stroke management.
86
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